Alkermes (ALKS) Cash from Financing Activities (2010 - 2026)
Alkermes' (ALKS) quarterly Cash from Financing Activities came in at $1.5 billion in Q1 2026, up 197292.1% year-on-year from N/an in Q1 2025, and up 13412.82% on a QoQ basis from $10.9 million in Q4 2025.
Alkermes (ALKS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Cash from Financing Activities data on file, last reported at $1.5 billion in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 197292.1% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 412.53% increase from a year earlier, with the FY2025 full-year figure at $12.4 million, up 102.51% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $1.5 billion, up from $10.9 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for ALKS reached as high as $1.5 billion in Q1 2026 and fell as low as -$281.7 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged $41.3 million across 5 years, with a median of -$212000.0 in 2022.
- Across the five-year window, Cash from Financing Activities plunged 101928.41% in 2023 and surged 197292.1% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at -$271000.0 in 2022, then plunged by 101928.41% to -$276.5 million in 2023, then dropped by 1.87% to -$281.7 million in 2024, then soared by 103.87% to $10.9 million in 2025, then jumped by 13412.82% to $1.5 billion in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $1.5 billion in Q1 2026, $10.9 million in Q4 2025, and $315000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 1.47 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.47 Bn |
| Mar 31, 2026 | 1.47 Bn |
| Dec 31, 2025 | 10.91 Mn |
| Dec 31, 2025 | 10.91 Mn |
| Sep 30, 2025 | 315,000.00 |
| Sep 30, 2025 | 315,000.00 |
| Jun 30, 2025 | 405,000.00 |
| Jun 30, 2025 | 405,000.00 |
| Mar 31, 2025 | 747,000.00 |
| Mar 31, 2025 | 747,000.00 |
| Dec 31, 2024 | -281.67 Mn |
| Dec 31, 2024 | -281.67 Mn |
| Sep 30, 2024 | -111.11 Mn |
| Sep 30, 2024 | -111.11 Mn |
| Jun 30, 2024 | -83.48 Mn |
| Jun 30, 2024 | -83.48 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Dec 31, 2023 | -276.50 Mn |
| Dec 31, 2023 | -276.50 Mn |